Astellas Pharma Stock News

Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying. The post Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion

Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs.

Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.

Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2022 Results Conference Call April 27, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representativ

Investors interested in Medical - Drugs stocks are likely familiar with Astellas Pharma Inc. (ALPMY) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunit

Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2022 Earnings Conference Call February 6, 2023 1:30 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Kenji Yasukawa - President

Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2022 Earnings Conference Call October 31, 2022 4:00 AM ET Company Representatives Kenji Yasukawa - Chief Executive Officer Yoshitsugu Shitaka - CScO, Chief Scient

Astellas Pharma, Inc. (OTCPK:ALPMF) Q1 2022 Earnings Conference Call August 1, 2022 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Minoru Kikuoka - CFO Yukio

ALPMY, AKZOY, and AVVID have been added to the Zacks Rank #5 (Strong Sell) List on June 22, 2022.

Twist Bioscience Corporation (NASDAQ: TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC: ALPMF) to conduct research activities t

Astellas Pharma, Inc. (OTCPK:ALPMF) Q4 2022 Results Conference Call April 27, 2022 1:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Kenji Yasukawa - President a

Astellas looks posed to exit a period of prolonged weak revenue growth and see acceleration into the mid-to-high single-digits on multiple product/indication approvals.

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (enfortumab vedotin-ejfv) in muscle-invasive bl

ESSA Pharma (EPIX) said the first patient was dosed in a phase 1/2 study of its lead product candidate EPI-7386, in combination with Astellas Pharma''s (ALPMF) and Pfizer''s…

ESSA Pharma Inc. (NASDAQ: EPIX ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA''s lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas Pharma Inc.''s ("Astellas") and Pfizer Inc.''s ligand-binding domain androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer ("mCRPC"). "The initiation of this combination trial with Astellas is a watershed moment for ESSA as we investigate the potential clinical benefit of inhibiting the androgen receptor through two independent pathways in the Full story available on Benzinga.com